Research and Markets: Protein Kinase Therapeutics in Oncology - Where To Commercialize? Analyses 133 Identified Targets of Protein Kinase Drugs, Organized Into 200 Drug Target Profiles

November 11, 2009 1:22 PM EST

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/ef5944/protein_kinase_the) has announced the addition of the "Protein Kinase Therapeutics in Oncology - Where to Commercialize?" report to their offering.

This report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. The report extensively analyses 133 identified targets of protein kinase drugs, organized into 200 drug target profiles, and assesses them in 57 different cancer indications.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies' portfolio planning and new product planning by:

    --  Providing you with competitive input to the R&D organization to guide
        development of early product ideas and ensure efforts are aligned with
        business objectives
    --  Assisting you to make informed decisions in selecting cancer indications
        that are known to be appropriate for your drug's properties
    --  Analyzing, correlating and integrating valuable data sources in order to
        provide accurate data for valuation of pipeline, in-licensing and new
        business opportunities
    --  Providing you with commercial analytic support for due diligence on
        in-licensing and acquisition opportunities
    --  Integrating knowledge for you to consider the therapeutic target for the
        highest therapeutic outcome and return on investment

This report will also be an important part of creating and implementing a market development plan for any protein kinase drug in oncology to ensure that the optimal market conditions exist by the time the product is commercialized.

Key Topics Covered:

    --  1 Executive Summary
    --  2 About Cancer Highlights
    --  3 Methodologies
    --  4 Overview
    --  5 Introduction
    --  6 Consider the Therapeutic Target for the Highest Therapeutic Outcome
        and Return on Investment
    --  7 The Rise of New Products: How Mature, Unique and Clinically Validated
        are the Drug Target Profiles Identified in the Cancer Protein Kinase
        Therapeutic Pipeline?
    --  8 Compound Strategies at Work: Competitive Benchmarking of Protein
        Kinase Drugs in Oncology by Compound Type
    --  9 Selecting Cancer Indications for Protein Kinase Therapeutics
    --  10 Portfolio Planning: Competitive Benchmarking of Protein Kinase Cancer
        Therapeutic Pipeline by Investigator
    --  11 Disclaimer
    --  12 Drug Index
    --  13 Company Index
    --  4.1 List of Figures
    --  4.1 List of Figures

Companies Mentioned:

    --  AB Science
    --  Abbott
    --  Bayer
    --  Cancer Research Technology
    --  Celgene
    --  Exelixis
    --  Galapagos
    --  Insmed
    --  Johnson & Johnson
    --  Kirin Pharma
    --  KuDOS
    --  Kyowa Hakko Kirin
    --  Novogen
    --  Oncalis
    --  Pfizer
    --  Provid
    --  QLT
    --  Quantum Pharmaceuticals
    --  Ras Therapeutics
    --  Sareum
    --  SBIO
    --  Scancell
    --  Schering-Plough
    --  ToolGen
    --  TopoTarget
    --  UCB
    --  VasGene Therapeutics
    --  ViroMed
    --  Wyeth
    --  Xencor

For more information visit http://www.researchandmarkets.com/research/ef5944/protein_kinase_the

    Source: Research and Markets

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?